Research programme: chimeric antigen receptor T cell therapeutics - Certainty Therapeutics

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - Certainty Therapeutics

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Certainty Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Follicle stimulating hormone modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 20 Nov 2017 ITUS Corporation and Moffitt Cancer Center agree to co-develop chimeric antigen receptor T cell therapeutics in Solid tumours
  • 14 Nov 2017 Certainty Therapeutics in-licenses CAR-T technology from Wistar Institute
  • 14 Nov 2017 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top